Nuvectis Pharma, Inc. (NVCT) Stock Competitors & Peer Comparison
See (NVCT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVCT | $19.29 | +6.99% | 506.3M | -14.56 | -$1.31 | N/A |
| VRTX | $472.57 | -1.96% | 119.9B | 25.11 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $651.18 | -3.56% | 67.1B | 14.27 | $45.63 | +0.56% |
| ARGX | $851.72 | -2.63% | 53B | 76.87 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $183.03 | -0.14% | 38.9B | -25.88 | -$7.07 | N/A |
| RVMDW | $8.83 | -0.34% | 37.7B | -2.13 | -$4.15 | N/A |
| ALNY | $266.99 | -1.61% | 35.6B | 48.11 | $5.55 | N/A |
| ONC | $319.93 | +3.01% | 34.1B | 71.29 | $4.47 | N/A |
Stock Comparison
NVCT vs VRTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, VRTX has a market cap of 119.9B. Regarding current trading prices, NVCT is priced at $19.29, while VRTX trades at $472.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas VRTX's P/E ratio is 25.11. In terms of profitability, NVCT's ROE is -1.48%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, NVCT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check VRTX's competition here
NVCT vs VRNA Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NVCT is priced at $19.29, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NVCT's ROE is -1.48%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, NVCT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check VRNA's competition here
NVCT vs REGN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, REGN has a market cap of 67.1B. Regarding current trading prices, NVCT is priced at $19.29, while REGN trades at $651.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas REGN's P/E ratio is 14.27. In terms of profitability, NVCT's ROE is -1.48%, compared to REGN's ROE of +0.14%. Regarding short-term risk, NVCT is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check REGN's competition here
NVCT vs ARGX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ARGX has a market cap of 53B. Regarding current trading prices, NVCT is priced at $19.29, while ARGX trades at $851.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ARGX's P/E ratio is 76.87. In terms of profitability, NVCT's ROE is -1.48%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, NVCT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ARGX's competition here
NVCT vs SGEN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NVCT is priced at $19.29, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NVCT's ROE is -1.48%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NVCT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check SGEN's competition here
NVCT vs RVMD Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, RVMD has a market cap of 38.9B. Regarding current trading prices, NVCT is priced at $19.29, while RVMD trades at $183.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas RVMD's P/E ratio is -25.88. In terms of profitability, NVCT's ROE is -1.48%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, NVCT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check RVMD's competition here
NVCT vs RVMDW Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, RVMDW has a market cap of 37.7B. Regarding current trading prices, NVCT is priced at $19.29, while RVMDW trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas RVMDW's P/E ratio is -2.13. In terms of profitability, NVCT's ROE is -1.48%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, NVCT is more volatile compared to RVMDW. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check RVMDW's competition here
NVCT vs ALNY Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ALNY has a market cap of 35.6B. Regarding current trading prices, NVCT is priced at $19.29, while ALNY trades at $266.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ALNY's P/E ratio is 48.11. In terms of profitability, NVCT's ROE is -1.48%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, NVCT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ALNY's competition here
NVCT vs ONC Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ONC has a market cap of 34.1B. Regarding current trading prices, NVCT is priced at $19.29, while ONC trades at $319.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ONC's P/E ratio is 71.29. In terms of profitability, NVCT's ROE is -1.48%, compared to ONC's ROE of +0.12%. Regarding short-term risk, NVCT is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ONC's competition here
NVCT vs ROIV Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, NVCT is priced at $19.29, while ROIV trades at $34.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ROIV's P/E ratio is -35.88. In terms of profitability, NVCT's ROE is -1.48%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, NVCT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ROIV's competition here
NVCT vs BNTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, BNTX has a market cap of 23.2B. Regarding current trading prices, NVCT is priced at $19.29, while BNTX trades at $91.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas BNTX's P/E ratio is -19.88. In terms of profitability, NVCT's ROE is -1.48%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, NVCT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check BNTX's competition here
NVCT vs INCY Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, INCY has a market cap of 23.1B. Regarding current trading prices, NVCT is priced at $19.29, while INCY trades at $115.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas INCY's P/E ratio is 15.56. In terms of profitability, NVCT's ROE is -1.48%, compared to INCY's ROE of +0.29%. Regarding short-term risk, NVCT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check INCY's competition here
NVCT vs INSM Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, INSM has a market cap of 23.1B. Regarding current trading prices, NVCT is priced at $19.29, while INSM trades at $106.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas INSM's P/E ratio is -18.55. In terms of profitability, NVCT's ROE is -1.48%, compared to INSM's ROE of -1.30%. Regarding short-term risk, NVCT is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check INSM's competition here
NVCT vs MRNA Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, MRNA has a market cap of 23B. Regarding current trading prices, NVCT is priced at $19.29, while MRNA trades at $58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas MRNA's P/E ratio is -7.13. In terms of profitability, NVCT's ROE is -1.48%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, NVCT is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check MRNA's competition here
NVCT vs UTHR Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, NVCT is priced at $19.29, while UTHR trades at $527.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas UTHR's P/E ratio is 19.46. In terms of profitability, NVCT's ROE is -1.48%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NVCT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check UTHR's competition here
NVCT vs BGNE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NVCT is priced at $19.29, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NVCT's ROE is -1.48%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, NVCT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check BGNE's competition here
NVCT vs DNA-WT Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NVCT is priced at $19.29, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NVCT's ROE is -1.48%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, NVCT is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check DNA-WT's competition here
NVCT vs GMAB Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, NVCT is priced at $19.29, while GMAB trades at $28.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas GMAB's P/E ratio is 20.76. In terms of profitability, NVCT's ROE is -1.48%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, NVCT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check GMAB's competition here
NVCT vs NBIX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, NBIX has a market cap of 17.4B. Regarding current trading prices, NVCT is priced at $19.29, while NBIX trades at $172.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas NBIX's P/E ratio is 24.96. In terms of profitability, NVCT's ROE is -1.48%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, NVCT is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check NBIX's competition here
NVCT vs BBIO Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, BBIO has a market cap of 16.2B. Regarding current trading prices, NVCT is priced at $19.29, while BBIO trades at $82.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas BBIO's P/E ratio is -22.10. In terms of profitability, NVCT's ROE is -1.48%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, NVCT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check BBIO's competition here
NVCT vs JAZZ Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, JAZZ has a market cap of 15.7B. Regarding current trading prices, NVCT is priced at $19.29, while JAZZ trades at $250.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas JAZZ's P/E ratio is 19.47. In terms of profitability, NVCT's ROE is -1.48%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, NVCT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check JAZZ's competition here
NVCT vs ASND Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ASND has a market cap of 15.6B. Regarding current trading prices, NVCT is priced at $19.29, while ASND trades at $251.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ASND's P/E ratio is -104.10. In terms of profitability, NVCT's ROE is -1.48%, compared to ASND's ROE of -56.42%. Regarding short-term risk, NVCT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ASND's competition here
NVCT vs EXEL Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, EXEL has a market cap of 13.8B. Regarding current trading prices, NVCT is priced at $19.29, while EXEL trades at $54.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas EXEL's P/E ratio is 16.46. In terms of profitability, NVCT's ROE is -1.48%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, NVCT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check EXEL's competition here
NVCT vs KRTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NVCT is priced at $19.29, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NVCT's ROE is -1.48%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NVCT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check KRTX's competition here
NVCT vs ARWR Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ARWR has a market cap of 12.5B. Regarding current trading prices, NVCT is priced at $19.29, while ARWR trades at $88.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ARWR's P/E ratio is -41.26. In terms of profitability, NVCT's ROE is -1.48%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, NVCT is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check ARWR's competition here
NVCT vs MDGL Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, NVCT is priced at $19.29, while MDGL trades at $537.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas MDGL's P/E ratio is -42.00. In terms of profitability, NVCT's ROE is -1.48%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, NVCT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check MDGL's competition here
NVCT vs AXSM Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, NVCT is priced at $19.29, while AXSM trades at $239.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas AXSM's P/E ratio is -62.56. In terms of profitability, NVCT's ROE is -1.48%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, NVCT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check AXSM's competition here
NVCT vs SMMT Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, SMMT has a market cap of 11.4B. Regarding current trading prices, NVCT is priced at $19.29, while SMMT trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas SMMT's P/E ratio is -9.21. In terms of profitability, NVCT's ROE is -1.48%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, NVCT is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check SMMT's competition here
NVCT vs BMRN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, NVCT is priced at $19.29, while BMRN trades at $58.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas BMRN's P/E ratio is 28.08. In terms of profitability, NVCT's ROE is -1.48%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, NVCT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check BMRN's competition here
NVCT vs RNAM Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NVCT is priced at $19.29, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NVCT's ROE is -1.48%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NVCT is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check RNAM's competition here
NVCT vs TECH Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, NVCT is priced at $19.29, while TECH trades at $71.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas TECH's P/E ratio is 37.00. In terms of profitability, NVCT's ROE is -1.48%, compared to TECH's ROE of +0.05%. Regarding short-term risk, NVCT is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check TECH's competition here
NVCT vs CYTK Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CYTK has a market cap of 10.2B. Regarding current trading prices, NVCT is priced at $19.29, while CYTK trades at $82.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CYTK's P/E ratio is -14.10. In terms of profitability, NVCT's ROE is -1.48%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, NVCT is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check CYTK's competition here
NVCT vs KRYS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, NVCT is priced at $19.29, while KRYS trades at $336.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas KRYS's P/E ratio is 45.03. In terms of profitability, NVCT's ROE is -1.48%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NVCT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check KRYS's competition here
NVCT vs RXDX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NVCT is priced at $19.29, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NVCT's ROE is -1.48%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NVCT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check RXDX's competition here
NVCT vs ABVX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ABVX has a market cap of 9.5B. Regarding current trading prices, NVCT is priced at $19.29, while ABVX trades at $129.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ABVX's P/E ratio is -68.00. In terms of profitability, NVCT's ROE is -1.48%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, NVCT is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ABVX's competition here
NVCT vs HALO Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, HALO has a market cap of 9.2B. Regarding current trading prices, NVCT is priced at $19.29, while HALO trades at $77.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas HALO's P/E ratio is 16.84. In terms of profitability, NVCT's ROE is -1.48%, compared to HALO's ROE of +1.26%. Regarding short-term risk, NVCT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check HALO's competition here
NVCT vs NUVL Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, NVCT is priced at $19.29, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas NUVL's P/E ratio is -21.79. In terms of profitability, NVCT's ROE is -1.48%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, NVCT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check NUVL's competition here
NVCT vs KYMR Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, NVCT is priced at $19.29, while KYMR trades at $110.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas KYMR's P/E ratio is -31.26. In terms of profitability, NVCT's ROE is -1.48%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, NVCT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check KYMR's competition here
NVCT vs IONS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, IONS has a market cap of 8.9B. Regarding current trading prices, NVCT is priced at $19.29, while IONS trades at $54.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas IONS's P/E ratio is -31.40. In terms of profitability, NVCT's ROE is -1.48%, compared to IONS's ROE of -0.59%. Regarding short-term risk, NVCT is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check IONS's competition here
NVCT vs CRNX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, NVCT is priced at $19.29, while CRNX trades at $83.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CRNX's P/E ratio is -16.32. In terms of profitability, NVCT's ROE is -1.48%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, NVCT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CRNX's competition here
NVCT vs ALKS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, NVCT is priced at $19.29, while ALKS trades at $52.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ALKS's P/E ratio is 55.35. In terms of profitability, NVCT's ROE is -1.48%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, NVCT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ALKS's competition here
NVCT vs IMGN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NVCT is priced at $19.29, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NVCT's ROE is -1.48%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NVCT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check IMGN's competition here
NVCT vs PTGX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, NVCT is priced at $19.29, while PTGX trades at $135.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas PTGX's P/E ratio is -74.83. In terms of profitability, NVCT's ROE is -1.48%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, NVCT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check PTGX's competition here
NVCT vs BPMC Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NVCT is priced at $19.29, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NVCT's ROE is -1.48%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, NVCT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check BPMC's competition here
NVCT vs APGE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, NVCT is priced at $19.29, while APGE trades at $134.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas APGE's P/E ratio is -30.97. In terms of profitability, NVCT's ROE is -1.48%, compared to APGE's ROE of -0.33%. Regarding short-term risk, NVCT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check APGE's competition here
NVCT vs CERE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NVCT is priced at $19.29, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CERE's P/E ratio is -16.47. In terms of profitability, NVCT's ROE is -1.48%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NVCT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CERE's competition here
NVCT vs PCVX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, NVCT is priced at $19.29, while PCVX trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas PCVX's P/E ratio is -8.14. In terms of profitability, NVCT's ROE is -1.48%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, NVCT is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check PCVX's competition here
NVCT vs TGTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, TGTX has a market cap of 8.1B. Regarding current trading prices, NVCT is priced at $19.29, while TGTX trades at $52.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas TGTX's P/E ratio is 18.10. In terms of profitability, NVCT's ROE is -1.48%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, NVCT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check TGTX's competition here
NVCT vs IMVT Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, NVCT is priced at $19.29, while IMVT trades at $39.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas IMVT's P/E ratio is -14.63. In terms of profitability, NVCT's ROE is -1.48%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, NVCT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check IMVT's competition here
NVCT vs IBRX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, NVCT is priced at $19.29, while IBRX trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas IBRX's P/E ratio is -8.84. In terms of profitability, NVCT's ROE is -1.48%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, NVCT is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check IBRX's competition here
NVCT vs MTSR Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NVCT is priced at $19.29, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NVCT's ROE is -1.48%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, NVCT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check MTSR's competition here
NVCT vs RYTM Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, RYTM has a market cap of 7.1B. Regarding current trading prices, NVCT is priced at $19.29, while RYTM trades at $103.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas RYTM's P/E ratio is -33.22. In terms of profitability, NVCT's ROE is -1.48%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, NVCT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check RYTM's competition here
NVCT vs MRUS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NVCT is priced at $19.29, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NVCT's ROE is -1.48%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, NVCT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check MRUS's competition here
NVCT vs COGT Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, NVCT is priced at $19.29, while COGT trades at $39.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas COGT's P/E ratio is -18.74. In terms of profitability, NVCT's ROE is -1.48%, compared to COGT's ROE of -0.83%. Regarding short-term risk, NVCT is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check COGT's competition here
NVCT vs ACLX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NVCT is priced at $19.29, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NVCT's ROE is -1.48%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NVCT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ACLX's competition here
NVCT vs PRAX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, PRAX has a market cap of 6.6B. Regarding current trading prices, NVCT is priced at $19.29, while PRAX trades at $312.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas PRAX's P/E ratio is -23.34. In terms of profitability, NVCT's ROE is -1.48%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, NVCT is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check PRAX's competition here
NVCT vs RETA Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NVCT is priced at $19.29, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas RETA's P/E ratio is -66.29. In terms of profitability, NVCT's ROE is -1.48%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NVCT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check RETA's competition here
NVCT vs PTCT Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, NVCT is priced at $19.29, while PTCT trades at $78.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas PTCT's P/E ratio is -33.65. In terms of profitability, NVCT's ROE is -1.48%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, NVCT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check PTCT's competition here
NVCT vs BLTE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, NVCT is priced at $19.29, while BLTE trades at $157.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas BLTE's P/E ratio is -84.03. In terms of profitability, NVCT's ROE is -1.48%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, NVCT is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check BLTE's competition here
NVCT vs CNTA Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, NVCT is priced at $19.29, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CNTA's P/E ratio is -22.63. In terms of profitability, NVCT's ROE is -1.48%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NVCT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CNTA's competition here
NVCT vs CGON Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, NVCT is priced at $19.29, while CGON trades at $69.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CGON's P/E ratio is -29.75. In terms of profitability, NVCT's ROE is -1.48%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NVCT is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check CGON's competition here
NVCT vs LGND Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, NVCT is priced at $19.29, while LGND trades at $304.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas LGND's P/E ratio is 36.48. In terms of profitability, NVCT's ROE is -1.48%, compared to LGND's ROE of +0.16%. Regarding short-term risk, NVCT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check LGND's competition here
NVCT vs ERAS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, NVCT is priced at $19.29, while ERAS trades at $19.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ERAS's P/E ratio is -20.98. In terms of profitability, NVCT's ROE is -1.48%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, NVCT is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check ERAS's competition here
NVCT vs SYRE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, SYRE has a market cap of 6B. Regarding current trading prices, NVCT is priced at $19.29, while SYRE trades at $99.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas SYRE's P/E ratio is -47.68. In terms of profitability, NVCT's ROE is -1.48%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, NVCT is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check SYRE's competition here
NVCT vs SRRK Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, NVCT is priced at $19.29, while SRRK trades at $48.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas SRRK's P/E ratio is -13.45. In terms of profitability, NVCT's ROE is -1.48%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, NVCT is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check SRRK's competition here
NVCT vs MIRM Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, MIRM has a market cap of 5.7B. Regarding current trading prices, NVCT is priced at $19.29, while MIRM trades at $114.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas MIRM's P/E ratio is -8.41. In terms of profitability, NVCT's ROE is -1.48%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, NVCT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check MIRM's competition here
NVCT vs CDTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NVCT is priced at $19.29, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NVCT's ROE is -1.48%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, NVCT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CDTX's competition here
NVCT vs ABCM Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NVCT is priced at $19.29, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NVCT's ROE is -1.48%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NVCT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ABCM's competition here
NVCT vs ISEE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NVCT is priced at $19.29, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NVCT's ROE is -1.48%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NVCT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ISEE's competition here
NVCT vs APLS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NVCT is priced at $19.29, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas APLS's P/E ratio is 38.35. In terms of profitability, NVCT's ROE is -1.48%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NVCT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check APLS's competition here
NVCT vs TVTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, NVCT is priced at $19.29, while TVTX trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas TVTX's P/E ratio is -255.73. In terms of profitability, NVCT's ROE is -1.48%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, NVCT is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check TVTX's competition here
NVCT vs XENE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, XENE has a market cap of 5.2B. Regarding current trading prices, NVCT is priced at $19.29, while XENE trades at $66.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas XENE's P/E ratio is -14.08. In terms of profitability, NVCT's ROE is -1.48%, compared to XENE's ROE of -0.49%. Regarding short-term risk, NVCT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check XENE's competition here
NVCT vs TERN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NVCT is priced at $19.29, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas TERN's P/E ratio is -51.41. In terms of profitability, NVCT's ROE is -1.48%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NVCT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check TERN's competition here
NVCT vs DFTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, NVCT is priced at $19.29, while DFTX trades at $43.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas DFTX's P/E ratio is N/A. In terms of profitability, NVCT's ROE is -1.48%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, NVCT is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check DFTX's competition here
NVCT vs MANE Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, NVCT is priced at $19.29, while MANE trades at $109.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas MANE's P/E ratio is -34.93. In terms of profitability, NVCT's ROE is -1.48%, compared to MANE's ROE of -0.84%. Regarding short-term risk, NVCT is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check MANE's competition here
NVCT vs CRSP Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, NVCT is priced at $19.29, while CRSP trades at $47.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CRSP's P/E ratio is -9.24. In terms of profitability, NVCT's ROE is -1.48%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, NVCT is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CRSP's competition here
NVCT vs FOLD Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NVCT is priced at $19.29, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NVCT's ROE is -1.48%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NVCT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check FOLD's competition here
NVCT vs AKRO Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NVCT is priced at $19.29, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NVCT's ROE is -1.48%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, NVCT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check AKRO's competition here
NVCT vs ALPN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NVCT is priced at $19.29, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NVCT's ROE is -1.48%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NVCT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ALPN's competition here
NVCT vs CELC Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, NVCT is priced at $19.29, while CELC trades at $90.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CELC's P/E ratio is -23.11. In terms of profitability, NVCT's ROE is -1.48%, compared to CELC's ROE of -2.45%. Regarding short-term risk, NVCT is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CELC's competition here
NVCT vs LEGN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, LEGN has a market cap of 4.4B. Regarding current trading prices, NVCT is priced at $19.29, while LEGN trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas LEGN's P/E ratio is -34.60. In terms of profitability, NVCT's ROE is -1.48%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, NVCT is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check LEGN's competition here
NVCT vs CAI Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CAI has a market cap of 4.3B. Regarding current trading prices, NVCT is priced at $19.29, while CAI trades at $15.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CAI's P/E ratio is -84.60. In terms of profitability, NVCT's ROE is -1.48%, compared to CAI's ROE of +0.06%. Regarding short-term risk, NVCT is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CAI's competition here
NVCT vs VKTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, NVCT is priced at $19.29, while VKTX trades at $37.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas VKTX's P/E ratio is -9.01. In terms of profitability, NVCT's ROE is -1.48%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, NVCT is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check VKTX's competition here
NVCT vs DNTH Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, NVCT is priced at $19.29, while DNTH trades at $102.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas DNTH's P/E ratio is -24.88. In terms of profitability, NVCT's ROE is -1.48%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, NVCT is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check DNTH's competition here
NVCT vs ACAD Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, NVCT is priced at $19.29, while ACAD trades at $24.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ACAD's P/E ratio is 12.24. In terms of profitability, NVCT's ROE is -1.48%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, NVCT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ACAD's competition here
NVCT vs OPT Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NVCT is priced at $19.29, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas OPT's P/E ratio is -1.52. In terms of profitability, NVCT's ROE is -1.48%, compared to OPT's ROE of +1.18%. Regarding short-term risk, NVCT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check OPT's competition here
NVCT vs EWTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, NVCT is priced at $19.29, while EWTX trades at $38.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas EWTX's P/E ratio is -23.09. In terms of profitability, NVCT's ROE is -1.48%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, NVCT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check EWTX's competition here
NVCT vs MRTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NVCT is priced at $19.29, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NVCT's ROE is -1.48%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NVCT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check MRTX's competition here
NVCT vs CPRX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, NVCT is priced at $19.29, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CPRX's P/E ratio is 12.30. In terms of profitability, NVCT's ROE is -1.48%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NVCT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CPRX's competition here
NVCT vs DYN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, DYN has a market cap of 3.8B. Regarding current trading prices, NVCT is priced at $19.29, while DYN trades at $23.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas DYN's P/E ratio is -7.21. In terms of profitability, NVCT's ROE is -1.48%, compared to DYN's ROE of -0.58%. Regarding short-term risk, NVCT is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check DYN's competition here
NVCT vs ELVN Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, NVCT is priced at $19.29, while ELVN trades at $52.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ELVN's P/E ratio is -31.65. In terms of profitability, NVCT's ROE is -1.48%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, NVCT is more volatile compared to ELVN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ELVN's competition here
NVCT vs DNLI Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, NVCT is priced at $19.29, while DNLI trades at $23.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas DNLI's P/E ratio is -8.21. In terms of profitability, NVCT's ROE is -1.48%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, NVCT is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check DNLI's competition here
NVCT vs RYZB Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NVCT is priced at $19.29, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NVCT's ROE is -1.48%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NVCT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check RYZB's competition here
NVCT vs CBAY Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NVCT is priced at $19.29, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NVCT's ROE is -1.48%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NVCT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check CBAY's competition here
NVCT vs NAMS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, NVCT is priced at $19.29, while NAMS trades at $31.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas NAMS's P/E ratio is -19.94. In terms of profitability, NVCT's ROE is -1.48%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, NVCT is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check NAMS's competition here
NVCT vs NAMSW Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, NVCT is priced at $19.29, while NAMSW trades at $19.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas NAMSW's P/E ratio is -10.50. In terms of profitability, NVCT's ROE is -1.48%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, NVCT is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check NAMSW's competition here
NVCT vs ALMS Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, NVCT is priced at $19.29, while ALMS trades at $28.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ALMS's P/E ratio is -7.35. In terms of profitability, NVCT's ROE is -1.48%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, NVCT is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCT.Check ALMS's competition here
NVCT vs SWTX Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NVCT is priced at $19.29, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NVCT's ROE is -1.48%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, NVCT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check SWTX's competition here
NVCT vs ORKA Comparison July 2026
NVCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCT stands at 506.3M. In comparison, ORKA has a market cap of 3.5B. Regarding current trading prices, NVCT is priced at $19.29, while ORKA trades at $92.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCT currently has a P/E ratio of -14.56, whereas ORKA's P/E ratio is -48.62. In terms of profitability, NVCT's ROE is -1.48%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, NVCT is more volatile compared to ORKA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCT.Check ORKA's competition here